tetano
Editor, Senior Moderator
Front Immunol
. 2022 Aug 12;13:939311.
doi: 10.3389/fimmu.2022.939311. eCollection 2022.
Immunogenicity and immune-persistence of the CoronaVac or Covilo inactivated COVID-19 Vaccine: a 6-month population-based cohort study
Qianhui Hua[SUP] 1 [/SUP], Hangjie Zhang[SUP] 2 [/SUP], Pingping Yao[SUP] 3 [/SUP], Nani Xu[SUP] 4 [/SUP], Yisheng Sun[SUP] 3 [/SUP], Hangjing Lu[SUP] 3 [/SUP], Fang Xu[SUP] 3 [/SUP], Yuting Liao[SUP] 5 [/SUP], Juan Yang[SUP] 5 [/SUP], Haiyan Mao[SUP] 3 [/SUP], Yanjun Zhang[SUP] 3 [/SUP], Hanping Zhu[SUP] 3 [/SUP], Xiaowei Hu[SUP] 4 [/SUP], Huakun Lv[SUP] 2 [/SUP], Jianmin Jiang[SUP] 2 [/SUP]
Affiliations
Abstract
Background: Owing to the coronavirus disease 2019 (COVID-19) pandemic and the emergency use of different types of COVID-19 vaccines, there is an urgent need to consider the effectiveness and persistence of different COVID-19 vaccines.
Methods: We investigated the immunogenicity of CoronaVac and Covilo, two inactivated vaccines against COVID-19 that each contain inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The levels of neutralizing antibodies to live SARS-CoV-2 and the inhibition rates of neutralizing antibodies to pseudovirus, as well as the immunoglobulin (Ig)G and IgM responses towards the spike (S) and nucleocapsid (N) protein of SARS-CoV-2 at 180 days after two-dose vaccination were detected.
Results: The CoronaVac and Covilo vaccines induced similar antibody responses. Regarding neutralizing antibodies to live SARS-CoV-2, 77.9% of the CoronaVac vaccine recipients and 78.3% of the Covilo vaccine recipients (aged 18-59 years) seroconverted by 28 days after the second vaccine dose. Regarding SARS-CoV-2-specific antibodies, 97.1% of the CoronaVac vaccine recipients and 95.7% of the Covilo vaccine recipients seroconverted by 28 days after the second vaccine dose. The inhibition rates of neutralizing antibody against a pseudovirus of the SARS-CoV-2 Delta variant were significantly lower compared with those against a pseudovirus of wildtype SARS-CoV-2. Associated with participant characteristics and antibody levels, persons in the older age group and with basic disease, especially a chronic respiratory disease, tended to have lower anti-SARS-CoV-2 antibody seroconversion rates.
Conclusion: Antibodies that were elicited by these two inactivated COVID-19 vaccines appeared to wane following their peak after the second vaccine dose, but they persisted at detectable levels through 6 months after the second vaccine dose, and the effectiveness of these antibodies against the Delta variant of SARS-CoV-2 was lower than their effectiveness against wildtype SARS-CoV-2, which suggests that attention must be paid to the protective effectiveness, and its persistence, of COVID-19 vaccines on SARS-CoV-2 variants.
Keywords: COVID-19; SARS-CoV-2; dynamic changes; immunogenicity; inactivated vaccine; persistence.
. 2022 Aug 12;13:939311.
doi: 10.3389/fimmu.2022.939311. eCollection 2022.
Immunogenicity and immune-persistence of the CoronaVac or Covilo inactivated COVID-19 Vaccine: a 6-month population-based cohort study
Qianhui Hua[SUP] 1 [/SUP], Hangjie Zhang[SUP] 2 [/SUP], Pingping Yao[SUP] 3 [/SUP], Nani Xu[SUP] 4 [/SUP], Yisheng Sun[SUP] 3 [/SUP], Hangjing Lu[SUP] 3 [/SUP], Fang Xu[SUP] 3 [/SUP], Yuting Liao[SUP] 5 [/SUP], Juan Yang[SUP] 5 [/SUP], Haiyan Mao[SUP] 3 [/SUP], Yanjun Zhang[SUP] 3 [/SUP], Hanping Zhu[SUP] 3 [/SUP], Xiaowei Hu[SUP] 4 [/SUP], Huakun Lv[SUP] 2 [/SUP], Jianmin Jiang[SUP] 2 [/SUP]
Affiliations
- PMID: 36032136
- PMCID: PMC9411798
- DOI: 10.3389/fimmu.2022.939311
Abstract
Background: Owing to the coronavirus disease 2019 (COVID-19) pandemic and the emergency use of different types of COVID-19 vaccines, there is an urgent need to consider the effectiveness and persistence of different COVID-19 vaccines.
Methods: We investigated the immunogenicity of CoronaVac and Covilo, two inactivated vaccines against COVID-19 that each contain inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The levels of neutralizing antibodies to live SARS-CoV-2 and the inhibition rates of neutralizing antibodies to pseudovirus, as well as the immunoglobulin (Ig)G and IgM responses towards the spike (S) and nucleocapsid (N) protein of SARS-CoV-2 at 180 days after two-dose vaccination were detected.
Results: The CoronaVac and Covilo vaccines induced similar antibody responses. Regarding neutralizing antibodies to live SARS-CoV-2, 77.9% of the CoronaVac vaccine recipients and 78.3% of the Covilo vaccine recipients (aged 18-59 years) seroconverted by 28 days after the second vaccine dose. Regarding SARS-CoV-2-specific antibodies, 97.1% of the CoronaVac vaccine recipients and 95.7% of the Covilo vaccine recipients seroconverted by 28 days after the second vaccine dose. The inhibition rates of neutralizing antibody against a pseudovirus of the SARS-CoV-2 Delta variant were significantly lower compared with those against a pseudovirus of wildtype SARS-CoV-2. Associated with participant characteristics and antibody levels, persons in the older age group and with basic disease, especially a chronic respiratory disease, tended to have lower anti-SARS-CoV-2 antibody seroconversion rates.
Conclusion: Antibodies that were elicited by these two inactivated COVID-19 vaccines appeared to wane following their peak after the second vaccine dose, but they persisted at detectable levels through 6 months after the second vaccine dose, and the effectiveness of these antibodies against the Delta variant of SARS-CoV-2 was lower than their effectiveness against wildtype SARS-CoV-2, which suggests that attention must be paid to the protective effectiveness, and its persistence, of COVID-19 vaccines on SARS-CoV-2 variants.
Keywords: COVID-19; SARS-CoV-2; dynamic changes; immunogenicity; inactivated vaccine; persistence.